

HALOZYME THERAPEUTICS INC  
 Form 4  
 May 20, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**KIRK RANDAL J**

2. Issuer Name and Ticker or Trading Symbol  
**HALOZYME THERAPEUTICS INC [HALO]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

**C/O THIRD SECURITY, LLC, 1881 GROVE AVENUE**

**05/16/2013**

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**RADFORD, VA 24141**

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |           |   |   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|-----------|---|---|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |                                   |           |   |   |
| Common Stock                    | 05/16/2013                           |  | A                              |   | 20,000<br><u>(1)</u>  | A  | \$ 0                              | 3,470,000 | D |   |
| Common Stock                    |                                      |  |                                |   |   |  |                                   | 2,685,415 | I | by R.J. Kirk DOT<br><u>(2)</u> <u>(3)</u>       |
| Common Stock                    |                                      |  |                                |   |   |  |                                   | 263,200   | I | by JPK<br>2012 <u>(2)</u> <u>(3)</u>            |
| Common Stock                    |                                      |  |                                |   |   |  |                                   | 42,319    | I | by Kellie L. Banks<br>LTT <u>(2)</u> <u>(3)</u> |

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

|              |           |   |                                 |
|--------------|-----------|---|---------------------------------|
| Common Stock | 3,977,445 | I | by Kapital Joe <sup>(3)</sup>   |
| Common Stock | 331,395   | I | by JPK 2009 <sup>(3)</sup>      |
| Common Stock | 331,394   | I | by MGK 2009 <sup>(3)</sup>      |
| Common Stock | 293,000   | I | by JPK 2008 <sup>(3)</sup>      |
| Common Stock | 293,000   | I | by MGK 2008 <sup>(3)</sup>      |
| Common Stock | 293,000   | I | by ZSK 2008 <sup>(3)</sup>      |
| Common Stock | 10,945    | I | by Lotus Capital <sup>(3)</sup> |
| Common Stock | 135,000   | I | by Staff 2001 <sup>(3)</sup>    |
| Common Stock | 1,326,320 | I | by NRM IV <sup>(3)</sup>        |
| Common Stock | 6,328,853 | I | by NRM V <sup>(3)</sup>         |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|  |  |                                      |  |                                |   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares  |
|  |  |                                      |  |                                |   | Code   | V   | (A)  | (D)   |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| KIRK RANDAL J<br>C/O THIRD SECURITY, LLC<br>1881 GROVE AVENUE<br>RADFORD, VA 24141 | X             | X         |         |       |

## Signatures

/s/ Randal J.  
Kirk

05/20/2013

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents annual restricted stock grant as compensation for services pursuant to the 2008 Outside Directors' Stock Plan. This grant will vest on the first day the outside director may trade Halozyme's common stock in compliance with Halozyme's Insider Trading Policy that occurs after the date immediately preceding the annual meeting following the date of grant.

(2) Kirkfield, L.L.C. was liquidated effective as of August 31, 2012, and in connection therewith the assets, including HALO shares held thereby, were distributed pro-rata to its members or their designees. Such liquidation constituted a change in form of beneficial ownership over the shares that were distributed to R.J. Kirk Declaration of Trust ("R.J. Kirk DOT"), JPK 2012, LLC ("JPK 2012") and the Kellie L. Banks (2009) Long Term Trust ("Kellie L. Banks LTT"). Randal J. Kirk continues to control each of R.J. Kirk DOT, JPK 2012 and Kellie L. Banks LTT.

(3) Randal J. Kirk controls each of R.J. Kirk DOT, JPK 2012, Kellie L. Banks LTT, Kapital Joe, LLC ("Kapital Joe"), JPK 2009, LLC ("JPK 2009"), MGK 2009, LLC ("MGK 2009"), JPK 2008, LLC ("JPK 2008"), MGK 2008, LLC ("MGK 2008"), ZSK 2008, LLC ("ZSK 2008"), Lotus Capital (2000) Company, Inc. ("Lotus Capital"), Third Security Staff 2001 LLC ("Staff 2001"), New River Management IV, LP ("NRM IV") and New River Management V, LP ("NRM V"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.